RIPK1 and metabolic dysfunction-associated steatohepatitis: In line with this study, Majdi [106] and colleagues showed that the inhibition of RIPK1 improved NASH characteristics in HFD-fed mice and reversed steatosis through an MLKL-dependent mechanism that mainly affects mitochondrial respiration.